Frank Gentile, Steve Lombardi, Norrie Russell, Peter Wilding, Charles Sie, Alan Guttmacher, Vence Bonham, Jr. | GenomeWeb

Frank Gentile has left his position as vice president for technology program management at Millennium Pharmaceuticals to join Boston-based investment firm Hambrecht & Quist Capital Management as vice president of research. Prior to working at Millennium, Gentile was vice president for product development at Curis. He is also an adjunct associate professor of biotechnology at Brown University.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.